BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M, Kumada T, Tanaka J. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterol 2022;22:241. [PMID: 35562658 DOI: 10.1186/s12876-022-02290-1] [Reference Citation Analysis]
3 Nielsen AS, Askgaard G, Thiele M. Treatment of alcohol use disorder in patients with liver disease. Curr Opin Pharmacol 2022;62:145-51. [PMID: 34999372 DOI: 10.1016/j.coph.2021.11.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
5 Guerra S, Mocciaro G, Gastaldelli A. "Adipose tissue insulin resistance and lipidome alterations are the characterizing factors of NASH". Eur J Clin Invest 2021;:e13695. [PMID: 34695228 DOI: 10.1111/eci.13695] [Reference Citation Analysis]
6 De Broucker C, Plessier A, Ollivier-Hourmand I, Dharancy S, Bureau C, Cervoni JP, Sogni P, Goria O, Corcos O, Sartoris R, Ronot M, Vilgrain V, de Raucourt E, Zekrini K, Davy H, Durand F, Payancé A, Fidouh-Houhou N, Yazdanpanah Y, Valla D, Rautou PE. Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. J Hepatol 2021:S0168-8278(21)02041-9. [PMID: 34563580 DOI: 10.1016/j.jhep.2021.09.011] [Reference Citation Analysis]
7 van Son KC, Tushuizen ME, Holleboom AG, Drenth JP. A non-invasive score for NAFLD cirrhosis. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.02.025] [Reference Citation Analysis]
8 Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol 2022:S0168-8278(22)00129-5. [PMID: 35271950 DOI: 10.1016/j.jhep.2022.02.022] [Reference Citation Analysis]
9 van Kleef LA, Sonneveld MJ, de Man RA, de Knegt RJ. Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline. J Hepatol 2021:S0168-8278(21)02012-2. [PMID: 34461208 DOI: 10.1016/j.jhep.2021.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. J Clin Med 2021;10:5755. [PMID: 34945051 DOI: 10.3390/jcm10245755] [Reference Citation Analysis]
11 Bugianesi E, Petta S. NAFLD/NASH. J Hepatol 2022:S0168-8278(22)00081-2. [PMID: 35513902 DOI: 10.1016/j.jhep.2022.02.006] [Reference Citation Analysis]
12 Nagai K, Ogawa Y, Kobayashi T, Iwaki M, Nogami A, Honda Y, Kessoku T, Saigusa Y, Imajo K, Yoneda M, Kirikoshi H, Komatsu T, Saito S, Nakajima A. Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography. JGH Open 2022;6:11-9. [DOI: 10.1002/jgh3.12689] [Reference Citation Analysis]
13 Huang Y, Gan Q, Lai R, Wang W, Guo S, Sheng Z, Chen L, Guo Q, Cai W, Wang H, Zhao G, Cao Z, Xie Q. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. Front Cell Infect Microbiol 2022;11:733348. [DOI: 10.3389/fcimb.2021.733348] [Reference Citation Analysis]
14 Venkatesh SK, Torbenson MS. Liver fibrosis quantification. Abdom Radiol (NY) 2022;47:1032-52. [PMID: 35022806 DOI: 10.1007/s00261-021-03396-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rosato V, Ascione A, Nevola R, Fracanzani AL, Piai G, Messina V, Claar E, Coppola C, Fontanella L, Lombardi R, Staiano L, Valente G, Fascione MC, Giorgione C, Mazzocca A, Galiero R, Perillo P, Marrone A, Sasso FC, Adinolfi LE, Rinaldi L. Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. J Viral Hepat 2021. [PMID: 34582610 DOI: 10.1111/jvh.13617] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines 2021;9:1370. [PMID: 34680486 DOI: 10.3390/biomedicines9101370] [Reference Citation Analysis]
17 Semmler G, Egger M, Hefner E, Datz C. Letter to Niezen and colleagues. Liver Int 2021;41:2525-6. [PMID: 34392604 DOI: 10.1111/liv.15037] [Reference Citation Analysis]
18 Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Reference Citation Analysis]
19 Decraecker M, Dutartre D, Hiriart JB, Irles-Depé M, Chermak F, Foucher J, de Lédinghen V. Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. Aliment Pharmacol Ther 2022. [PMID: 34978351 DOI: 10.1111/apt.16760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
21 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
22 Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. Hepatol Commun 2022. [PMID: 35666055 DOI: 10.1002/hep4.2015] [Reference Citation Analysis]
23 Ratziu V, Anstee QM, Wong VW, Schattenberg JM, Bugianesi E, Augustin S, Gheorghe L, Zambon V, Reau N. An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. Hepatology 2022. [PMID: 35363906 DOI: 10.1002/hep.32500] [Reference Citation Analysis]
24 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Reference Citation Analysis]
25 Balkhed W, Åberg FO, Nasr P, Ekstedt M, Kechagias S. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study. Liver Int 2022. [PMID: 35319156 DOI: 10.1111/liv.15255] [Reference Citation Analysis]
26 Li W, Alamoudi JA, Gautam N, Kumar D, Olivera M, Gwon Y, Mukgerjee S, Alnouti Y, Santra A. Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. International Journal of Hepatology 2022;2022:1-17. [DOI: 10.1155/2022/5473752] [Reference Citation Analysis]
27 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
28 Loosen SH, Kostev K, Keitel V, Tacke F, Roderburg C, Luedde T. An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. J Hepatol 2021:S0168-8278(21)02028-6. [PMID: 34520785 DOI: 10.1016/j.jhep.2021.08.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Trifan A, Rotaru A, Stafie R, Stratina E, Zenovia S, Nastasa R, Huiban L, Cuciureanu T, Muzîca C, Chiriac S, Gîrleanu I, Sîngeap A, Sfarti C, Cojocariu C, Stanciu C. Clinical and Laboratory Characteristics of Normal Weight and Obese Individuals with Non-Alcoholic Fatty Liver Disease. Diagnostics 2022;12:801. [DOI: 10.3390/diagnostics12040801] [Reference Citation Analysis]
30 Hsieh M, Kao T, Hsieh T, Kao C, Peng C, Lai H, Chuang P, Kao J. Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study. Therapeutic Advances in Chronic Disease 2022;13:204062232110676. [DOI: 10.1177/20406223211067631] [Reference Citation Analysis]
31 Sarabia Aldana CA, Medina-torres L, Calderas F, Ramírez-torres LA, Núñez-ramírez D, Herrera-valencia EE, Bernad-bernad MJ, Manero O. Hemorheological and biochemical study in patients with liver cirrhosis. Physics of Fluids 2022;34:041907. [DOI: 10.1063/5.0086561] [Reference Citation Analysis]
32 Androutsakos T, Voulgaris TA, Bakasis A, Koutsompina M, Chatzis L, Argyropoulou OD, Pezoulas V, Fotiadis DI, Papatheodoridis G, Tzioufas AG, Goules AV. Liver Fibrosis in Primary Sjögren’s Syndrome. Front Immunol 2022;13:889021. [DOI: 10.3389/fimmu.2022.889021] [Reference Citation Analysis]
33 Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ. Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. Front Pharmacol 2021;12:768576. [PMID: 34759828 DOI: 10.3389/fphar.2021.768576] [Reference Citation Analysis]
34 Loosen S, Luedde M, Demir M, Luedde T, Kostev K, Roderburg C. An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137 842 patients with and without chronic liver disease. Eur J Gastroenterol Hepatol 2022;34:717-23. [PMID: 35412485 DOI: 10.1097/MEG.0000000000002377] [Reference Citation Analysis]
35 Reiberger T. The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis. Hepatol Commun 2021. [PMID: 34904404 DOI: 10.1002/hep4.1855] [Reference Citation Analysis]
36 Schöler D, Kostev K, Demir M, Luedde M, Konrad M, Luedde T, Roderburg C, Loosen SH. An Elevated FIB-4 Score Is Associated with an Increased Incidence of Depression among Outpatients in Germany. JCM 2022;11:2214. [DOI: 10.3390/jcm11082214] [Reference Citation Analysis]
37 Han E, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707). Diabetes Metab J 2021;45:972-3. [PMID: 34847647 DOI: 10.4093/dmj.2021.0315] [Reference Citation Analysis]
38 Cossiga V, Sanduzzi-Zamparelli M, Sapena V, Guarino M, Dallio M, Torrisi E, Pignata L, Federico A, Salomone F, Morisco F. Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study. Front Pharmacol 2022;13:824879. [PMID: 35185575 DOI: 10.3389/fphar.2022.824879] [Reference Citation Analysis]
39 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update". J Hepatol 2021:S0168-8278(21)02114-0. [PMID: 34742599 DOI: 10.1016/j.jhep.2021.10.008] [Reference Citation Analysis]
40 Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel) 2021;11:2236. [PMID: 34943471 DOI: 10.3390/diagnostics11122236] [Reference Citation Analysis]
41 Le Garf S, Nègre V, Anty R, Gual P. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Biomedicines 2021;9:1915. [PMID: 34944730 DOI: 10.3390/biomedicines9121915] [Reference Citation Analysis]
42 Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KW. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102064] [Reference Citation Analysis]
43 Zhao Y, Li H. Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease. Scand J Gastroenterol 2022;:1-6. [PMID: 35189786 DOI: 10.1080/00365521.2022.2041085] [Reference Citation Analysis]
44 Amin NB, Darekar A, Anstee QM, Wong VW, Tacke F, Vourvahis M, Lee DS, Charlton M, Alkhouri N, Nakajima A, Yunis C. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open 2022;12:e056159. [PMID: 35354614 DOI: 10.1136/bmjopen-2021-056159] [Reference Citation Analysis]
45 Liu C, Li J, Wong YJ, Xie Q, Hirooka M, Enomoto H, Kim TH, Hanafy AS, He R, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Jung YK, Yim HJ, Ma J, Zeng QL, Sarin SK, Qi X. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study. Hepatol Int 2022. [PMID: 35606627 DOI: 10.1007/s12072-022-10345-4] [Reference Citation Analysis]
46 van Kleef LA, Lu Z, Ikram MA, de Groot NM, Kavousi M, de Knegt RJ. LIVER STIFFNESS, BUT NOT FATTY LIVER DISEASE, IS ASSOCIATED WITH ATRIAL FIBRILLATION: THE ROTTERDAM STUDY. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.05.030] [Reference Citation Analysis]
47 Liu Y, Liu C, Li J, Kim TH, Enomoto H, Qi X. Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102). J Hepatol 2021:S0168-8278(21)02112-7. [PMID: 34662676 DOI: 10.1016/j.jhep.2021.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F. Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100480] [Reference Citation Analysis]
49 Michel M, Labenz C, Anders M, Wahl A, Girolstein L, Kaps L, Kremer WM, Huber Y, Galle PR, Sprinzl M, Schattenberg JM. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatol Commun 2022. [PMID: 35411570 DOI: 10.1002/hep4.1958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Mak AL, Lee J, van Dijk AM, Vali Y, Aithal GP, Schattenberg JM, Anstee QM, Brosnan MJ, Zafarmand MH, Ramsoekh D, Harrison SA, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1920. [PMID: 34944736 DOI: 10.3390/biomedicines9121920] [Reference Citation Analysis]
51 Welman CJ, Saunders J, Zelesco M, Abbott S, Boardman G, Ayonrinde OT. Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation. J Med Imaging Radiat Oncol 2022. [PMID: 35466506 DOI: 10.1111/1754-9485.13412] [Reference Citation Analysis]
52 Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Hui WZ, Sook Yee NT, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01280-5. [PMID: 34890795 DOI: 10.1016/j.cgh.2021.12.002] [Reference Citation Analysis]
53 Loosen SH, Kostev K, Demir M, Luedde M, Keitel V, Luedde T, Roderburg C. An elevated FIB-4 score is associated with an increased incidence of liver cancer: A longitudinal analysis among 248,224 outpatients in Germany. European Journal of Cancer 2022;168:41-50. [DOI: 10.1016/j.ejca.2022.03.010] [Reference Citation Analysis]
54 Bastati N, Beer L, Ba-Ssalamah A, Poetter-Lang S, Ambros R, Kristic A, Lauber D, Pomej K, Binter T, Simbrunner B, Semmler G, Balcar L, Bican Y, Hodge JC, Wrba T, Trauner M, Reiberger T, Mandorfer M. Gadoxetic Acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and Spleen Diameter Predict Outcomes in ACLD. J Hepatol 2022:S0168-8278(22)00268-9. [PMID: 35525337 DOI: 10.1016/j.jhep.2022.04.032] [Reference Citation Analysis]
55 Nam D, Chapiro J, Paradis V, Seraphin TP, Kather JN. Artificial intelligence in liver diseases: improving diagnostics, prognostics and response prediction. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100443] [Reference Citation Analysis]
56 Roeb E. Nichtalkoholische Steatohepatitis (NASH) und alkoholische Steatohepatitis (ASH). Drug Res (Stuttg) 2021;71:S16-8. [PMID: 34788881 DOI: 10.1055/a-1606-5858] [Reference Citation Analysis]
57 Majumdar A, Tsochatzis EA. Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? Gut 2022;71:1236-7. [PMID: 34521766 DOI: 10.1136/gutjnl-2021-325994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Baldini F, Khalil M, Bartolozzi A, Vassalli M, Di Ciaula A, Portincasa P, Vergani L. Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and In Vitro Studies. Biomolecules 2022;12:733. [PMID: 35625660 DOI: 10.3390/biom12050733] [Reference Citation Analysis]
59 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules 2022;12:105. [DOI: 10.3390/biom12010105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Calès P, Ravaioli F, Berger A, Farcau O, Festi D, Stefanescu H, Vitellius C, Nahon P, Bureau C, Ganne-carriè N, Berzigotti A, de Ledinghen V, Petta S. Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101925] [Reference Citation Analysis]
61 Vitellius C, Paisant A, Lannes A, Chaigneau J, Oberti F, Lebigot J, Fouchard I, Boursier J, David P, Aubé C, Calès P; CDMIR group. Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses. Clin Res Hepatol Gastroenterol 2021;46:101797. [PMID: 34500117 DOI: 10.1016/j.clinre.2021.101797] [Reference Citation Analysis]
62 Liu Y, Tang T, Örmeci N, Huang Y, Wang J, Li X, Li Z, An W, Liu D, Zhang C, Liu C, Liu J, Liu C, Wang G, Mosconi C, Cappelli A, Bruno A, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Li L, Zhang H, Kang N, Xu D, He R, Wang Y, Bu Y, Gu Y, Ju S, Golfieri R, Qi X. Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. J Clin Transl Hepatol 2021;9:818-27. [PMID: 34966645 DOI: 10.14218/JCTH.2021.00177] [Reference Citation Analysis]
63 Hwang TI, Han AL. Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease. Int J Environ Res Public Health 2021;18:13145. [PMID: 34948754 DOI: 10.3390/ijerph182413145] [Reference Citation Analysis]
64 Miao X, Sha T, Zhang W, Zhou H, Qiu C, Deng H, You Y, Ren J, Zhang X, Zheng R, Yin T. Liver Fibrosis Assessment by Viewing Sinusoidal Capillarization: US Molecular Imaging versus Two-dimensional Shear-Wave Elastography in Rats. Radiology 2022;:212325. [PMID: 35503015 DOI: 10.1148/radiol.212325] [Reference Citation Analysis]
65 Canivet CM, Smati S, Lannes A, Brisseau J, Judon L, Roch ML, Cariou B, Bellanger W, Guerci B, Boursier J. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clin Res Hepatol Gastroenterol 2021;:101848. [PMID: 34922062 DOI: 10.1016/j.clinre.2021.101848] [Reference Citation Analysis]
66 Thanapirom K, Suksawatamnuay S, Tanpowpong N, Chaopathomkul B, Sriphoosanaphan S, Thaimai P, Srisoonthorn N, Treeprasertsuk S, Komolmit P. Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study. Sci Rep 2022;12:4913. [PMID: 35318425 DOI: 10.1038/s41598-022-08955-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol 2021:S0168-8278(21)02228-5. [PMID: 34856322 DOI: 10.1016/j.jhep.2021.11.023] [Reference Citation Analysis]
68 Baselli GA, Jamialahmadi O, Pelusi S, Ciociola E, Malvestiti F, Saracino M, Santoro L, Cherubini A, Dongiovanni P, Maggioni M, Bianco C, Tavaglione F, Cespiati A, Mancina RM, D’ambrosio R, Vaira V, Petta S, Miele L, Vespasiani-gentilucci U, Federico A, Pihlajamaki J, Bugianesi E, Fracanzani AL, Reeves HL, Soardo G, Prati D, Romeo S, Valenti LV, Borroni V, Liguori A, Ronzoni L, Cherubini A, Santoro L, Tomasi M, Lombardi A, Ostadreza M, Casirati E, Marini I, Maier S, Rosso C, Baroni GS, Santaniello C, Dallio M. Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.031] [Reference Citation Analysis]